Finland· FI-REL-REL56953
Zenalpha
A muut unilääkkeet product containing medetomidine hydrochloride + vatinoxan hydrochloride, registered in Finland by Vetcare Oy.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Medetomidine hydrochloride + Vatinoxan hydrochloride
- Manufacturer
- Vetcare Oy
- Country
- Finland (FI)
- ATC code
- QN05CM
- ATC class
- Muut unilääkkeet
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Medetomidine hydrochloride + vatinoxan hydrochloride in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf4fb599-5128-4be2-bc14-b30c48db0465 GET /v1/drugs/bf4fb599-5128-4be2-bc14-b30c48db0465?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos",
"route": "Lihakseen",
"ddd_unit": null,
"strength": "0.5 mg/ml + 10 mg/ml",
"atc_label": "Muut unilääkkeet",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/2/21/279/001-003",
"fimea_rel_id": "REL56953",
"authorised_at": "2021-12-15"
}See everything about medetomidine hydrochloride + vatinoxan hydrochloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.